1. Home
  2. ADVM

as 09-05-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Founded: 2006 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 66.3M IPO Year: 2014
Target Price: $19.75 AVG Volume (30 days): 87.6K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -8.10 EPS Growth: N/A
52 Week Low/High: $1.78 - $8.56 Next Earning Date: 11-03-2025
Revenue: $1,000,000 Revenue Growth: -72.22%
Revenue Growth (this year): 1836.7% Revenue Growth (next year): -97.62%

ADVM Daily Stock ML Predictions

Share on Social Networks: